In July of this year, the National Academies of Science, Medicine, and Engineering (NASEM) released a report titled, “Returning Individual Research Results to Participants: Guidance for a New Research Paradigm.” It’s a comprehensive report that raises many important considerations and proposes a number of thoughtful recommendations on this very timely topic. I won’t be able to do justice to all of its details and nuance here. Instead, I’ll share what I take to be some key themes and takeaways, including for IRBs. Read more
You are a physician at a Catholic hospital investigating a new treatment for a women’s health condition. This healthy volunteer study requires an unpleasant and somewhat risky procedure, so you do not expect to meet your enrollment target. The first five participants are nuns who say their primary motivation is altruism. What, if anything, should you do? Read more
Have you been keeping up with PRIM&R in the news? Here are some recent articles written or contributed to by PRIM&R’s executive director, Elisa A. Hurley, PhD, regarding lab animal oversight and the revised Common Rule. Read more
Expanded access, which is treatment access to experimental drugs (also referred to as "compassionate use" or "pre-approval access"), has generated increasing interest and debate over the last several years. On March 7, PRIM&R hosted a webinar, Pre-Approval Access to Drugs in Development: Navigating the Changing Regulatory, Ethical, and Legal Landscape, to educate HRPP professionals on FDA guidance, recent legislation, and ethical questions related to expanded access. The webinar featured Richard Klein, the former director of the FDA's Patient Liaison Program in the Office of Health and Constituent Affairs, and Beth E. Roxland, JD, MBioethics, an Attorney, Bioethicist, and Senior Advisor on Law, Health Policy and Ethics at Roxland Consultants, Ltd. After the webinar, Mr. Klein responded to some of the attendee questions time didn’t permit us to address live. We’re pleased to share those responses with the readers of Ampersand. Read more
This edition of Research Ethics Roundup covers the favorability of animal research among Americans, a hostile workplace in an empathy research lab, conflicts of interest in Vitamin D deficiency research, and plagiarism in breast cancer research. Read more
Welcome to Research Ethics Reading List, a new feature from Ampersand where we feature books in or adjacent to the field of research ethics that we think you’ll find interesting, motivating, inspiring, challenging, or some combination of the four! In this edition we look at books about tech industry bias and blind spots; the powers, perversions, and potential of heredity; animal Infections and the next human pandemic; and more! Read more
On May 30, 2018, the four-year Right to Try (RTT) movement culminated in a new federal law, with the stated goal of providing terminally ill patients with a new route of access to early phase investigational drugs that are currently in clinical development and not approved or generally available to all patients in need.
RTT laws seek to remove federal FDA oversight and regulations from the pre-approval process, in which patients seek to access experimental drugs in development outside of the clinical trials in which the drugs are being tested, despite the fact that terminally ill patients already had the right to request such access under FDA regulations for decades through the Expanded Access Program. Read more